compounding glp-1 enforcement news Patients struggle as compounded access rapidly shrinks Troubling Findings in Study of

[1][2] Why CVS Caremark Chose Wegovy Novo Nordisk deal: CVS Caremark negotiated preferred pricing for Wegovy, making it their primary GLP-1 option Zepbound removed: Eli Lilly's Zepbound was dropped from CVS Caremark formularies in July 2025 Cardiovascular benefit: Wegovy is the only GLP-1 FDA-approved for both weight loss AND cardiovascular risk reduction What This Means for Aetna Members Standard Aetna plans: Wegovy is covered with prior authorization Self-funded employer plans: May have different formulariescheck with HR Medicare Advantage: Coverage varies by plansee Medicare guide For more details on how CVS Caremark affects GLP-1 coverage across all insurers: Complete CVS Caremark Guide Now that you understand why Wegovy is preferred, here's what you need for prior authorization approval

A cross sectional study

For example, when switching between formulations such as from oral to injectable semaglutide ensure equivalent dosing

Which GLP-1 drug is best for weight loss